Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialSteven E. Lipshultz, Steven D. Colan, Rebecca E. Scully et al.|The Lancet Oncology|2010Cited by 452
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemiaNobuko Hijiya, Paul S. Gaynon, Elly Barry et al.|Blood|2011Cited by 122
Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With DexrazoxaneElly Barry, Lewis B. Silverman, Lynda M. Vrooman et al.|Journal of Clinical Oncology|2008Cited by 119
A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemiaNobuko Hijiya, William L. Carroll, Paul S. Gaynon et al.|Leukemia|2009Cited by 86
Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute LeukemiaNobuko Hijiya, William L. Carroll, Paul S. Gaynon et al.|Blood|2008Cited by 9